Research & Development

Research and Development

In addition to the primary organic expansion of our NDA and ANDA generic submissions, Brogan actively participates and supports the development of new technologies and chemical entities that are able to be designated as orphan drugs or devices.

Participation on the research, development and commercialization of Orphan Drug products or devices is in the form of direct investment, SBIR-STTR grants and royalties.  We work closely with CRO's and individual researches to perfect the most suitable funding and resource allocation for the primary pre-clinical and clinical work.  Projects can be performed at our facilities or at the primary researchers.